Intellia Therapeutics, Inc. (NTLA)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a NASDAQ-listed Biotechnology company developing genomic medicines through genome editing, with both in vivo and ex vivo programs. In FY2025, the company recorded $67.7 million in revenue. Intellia operates in the healthcare sector and centers its platform on CRISPR/Cas9-based therapeutic development.
Today's Snapshot
NTLA ended yesterday 4.2% down at 12.21. Intellia secured priority review from the U.S. Food and Drug Administration for its one-time CRISPR treatment for hereditary angioedema.
Trading Volume
Above 10d avg 3.2M
4.9M
vs S&P 500 Today
Strong Underperformance
-3.68%
Updated: September 10, 2026 at 12:16 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$12.56 - $13.23Sell
- RSI (14)45.78Neutral
- Stochastic %K (14, 3, 3)33.50Neutral
- MACD Level (12, 26)0.08Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.